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The development of depressive symptomatology is a recognised complication of 
treatment with the cytokine, interferon-α, and has been seen as supporting 
inflammatory theories of the pathophysiology of major depression. Major depression 
has been associated with changes in glutamatergic activity and recent formulations of 
interferon-induced depression have implicated neurotoxic influences which could also 
lead to changes in glutamate function. The present study used magnetic resonance 
spectroscopy (MRS) to measure both glutamate and its major metabolite, glutamine in 
patients with hepatitis C who received treatment with pegylated-interferon-α and 
ribavirin. 
Methods 
MRS measurements of glutamate and glutamine were taken from a 25x20x20mm 
voxel including pregenual anterior cingulate cortex in 12 patients before and after 4-6 
weeks treatment with interferon. 
Results 
Interferon treatment led to an increase in cortical levels of glutamine (p= 0.02) and a 
significant elevation in the ratio of glutamine to glutamate (p<.01). Further, changes 
in glutamine level correlated significantly with ratings of depression and anxiety at 
the time of the second scan. 
Conclusions 
We conclude that treatment with interferon-α is associated with MRS-visible changes 
in glutamatergic metabolism. However, the changes seen differ from those reported in 
major depression which suggests that the pathophysiology of interferon-induced 
depression may be distinct from that of major depression more generally.   
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Introduction 
Administration of interferon-α (IFN-α) for the treatment of hepatitis C is associated 
with a significant incidence of depressive symptomatology, with up to 40% of 
patients developing major depression over three months of IFN-α therapy (Hauser et 
al. 2002, Raison et al. 2005, Leutscher et al. 2010). This observation has been taken as 
evidence of the possible role of inflammatory mechanisms in the pathophysiology of 
major depression more generally (Raison et al. 2006), and is consistent with reports of 
elevated plasma levels of pro-inflammatory mediators such as tumor necrosis factor 
(TNF) and interleukin-6 (IL-6) in depressed patients (Dowlati et al. 2010). 
 
The mechanism by which IFN-α might produce depression has been explored in 
several previous studies. One potential mechanism involves induction of indoleamine 
2,3 dioxygenase (IDO) with consequent alterations in the metabolism of the serotonin 
precursor, tryptophan. While central tryptophan depletion was originally suggested as 
a cause of IFN-α-induced depression (Bonaccorso et al. 2000, Capuron et al. 2002), 
more recent formulations have implicated increased production of tryptophan 
metabolites such as quinolinic and kynurenic acids which have the potential to alter 
central glutamatergic neurotransmission (Wichers and Maes 2004, Miller et al. 2009, 
Raison et al. 2010). It has also been suggested that the response to inflammatory 
mediators such as IFN-α might include impairment of the ability of astrocytes to take 
up synaptic glutamate, thus predisposing to glutamate toxicity (Tavares et al. 2002, 
McNally et al. 2008). This is of interest in view of the postulated role of glutamate 
abnormalities (Sanacora et al. 2008) and glial cell deficits (Rajkowska et al. 2007) in 
major depression.  
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Magnetic Resonance Spectroscopy (MRS) provides a safe non-invasive method for 
measurement of cortical glutamate. A growing number of studies demonstrate MRS 
abnormalities in glutamine and glutamate in brain regions such as anterior cingulate 
cortex in mood disorders (Yüksel et al. 2010). Typically, reliable differentiation of 
glutamate from glutamine with MRS is highly challenging so the combined total 
glutamate with glutamine, often termed Glx, is reported. Recent technical advances 
allow for more confident estimation of glutamate and glutamine individually (Mekle 
et al. 2009). This is an important development, since while Glx reflects a total 
glutamatergic pool, the ratio of glutamine to glutamate is believed to more closely 
reflect glutamatergic function (Théberge et al. 2002, Yüksel et al. 2010).  
 
The aim of the present study was to use proton MRS to assess the effect of IFN-α on 
cerebral glutamate and glutamine levels in patients receiving IFN-α treatment for the 
management of hepatitis C. We also investigated whether changes in these brain 
neurochemicals correlated with emergent depressive symptomatology.  




We recruited 17 participants, aged between 18 and 65, who had chronic hepatitis C 
viral infection without evidence of cirrhosis, and were scheduled to receive treatment 
with pegylated-interferon-α and ribavirin (IFN) as part of their routine clinical care. 
Participants were recruited from NHS hepatology clinics at two centres (Oxford and 
Bristol, UK). They were scanned at baseline, prior to starting treatment, and again 
after 4-6 weeks of treatment with IFN. Those with current DSM-IV axis I disorders 
by Structured Clinical Interview (First et al. 2002), taking a non-stable dose of 
psychotropic medication, or with any contraindication to MR scanning were excluded. 
Clinical or biochemical evidence of cirrhosis was an exclusion criterion and all 
participants had had liver biopsy or fibroscan. Past psychiatric history such as history 
of opiate dependence was not an exclusion criterion. Concomitant medication was 
continued at the same dose throughout the study. The majority of participants (16 of 
17) were taking no psychotropic medication, the remaining participant was taking a 
low dose antidepressant, but does not contribute to the glutamine analyses presented 
below. Patients were included taking vitamin supplements, erythromycin, thyroxine, 
the oral contraceptive pill and regular inhalers. The study was approved by the 
Oxfordshire Research Ethics Committee A and all participants gave written informed 
consent. Participants were reimbursed for their time and any other expenses. 
 
Imaging was performed on a 3 Tesla Siemens TIM Trio scanner with a body coil 
transmitter and a 12-channel head receiver array. MRS measurements were obtained 
from a 25x20x20mm voxel of medial prefrontal cortex including pregenual anterior 
cingulate cortex (Figure 1B) using SPECIAL (Mekle et al. 2009) with TR/TE: 
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3000/8.5ms. Water suppressed (192 averages) and water unsuppressed data (8 
averages) were obtained. The voxel was positioned manually by reference to an axial 
T1-weighted gradient-echo image. Prior to spectral analysis, motion corrupted 
averages were discarded, and the effects of scanner drift were removed by performing 
a frequency and phase alignment of the averages.  Spectra were analysed with 
LCModel version 6.2 (Provencher 1993) using a set of simulated metabolite basis 
spectra. Eddy current correction was employed. Metabolite estimates with Cramér-
Rao Lower Bounds (CRLB) >20% were excluded. One baseline glutamine estimate 
was excluded for this reason. Concentrations were expressed relative to creatine (Cr), 
and ratio of glutamate to glutamine also calculated. In a secondary analysis, 
concentrations relative to tissue water were also calculated. T1-weighted structural 
images of whole brain were acquired with 1mm3 voxel resolution. FSL FAST was 
employed to segment the structural brain images into grey matter, white matter, and 
CSF, to allow estimation of voxel composition. 
 
Ratings 
Self-report measures of mental state were obtained at baseline and at the time of 
second scan using the 16 item self-report Quick Inventory of Depressive 
Symptomatology (QIDS, Rush et al. 2003), Spielberger State Anxiety (STAI, 
Spielberger et al. 1970) and the Fatigue Severity Scale (FSS, Krupp et al. 1989). FSS 
ratings were not available for three participants (Table 1). 
 
Statistics 
Group comparisons were performed using the general linear model in PASW 
Statistics v18 (SPSS Inc). MRS measures were tested for correlation with age and 
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voxel composition. No significant effects were seen so these were not included as 
covariates in the model. Correlations were tested using Pearson’s r. All statistical tests 
were two-tailed with 0.05 significance level.
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Results 
Imaging data were obtained at baseline and during IFN treatment from 12 patients 
with chronic hepatitis C. Of the seventeen patients recruited, one did not tolerate 
baseline scanning, two withdrew before completing the protocol, and for two the 
MRS acquisition failed for technical reasons. Six of the twelve patients demonstrated 
a rapid virologic response with undetectable serum viral load at week four of 
treatment. Treatment was associated with a statistically significant increase in 
depression symptoms (p=0.01; Table 1) but not in anxiety or fatigue ratings (p>0.15 
both cases).  
Table 1 near here 
 
IFN treatment was associated with a significant increase in anterior cingulate cortex 
glutamine levels (Gln/Cr baseline 0.40 ± .10, IFN 0.50 ± .12, p=0.02; Figure 1C). No 
effect on glutamate was observed (p>0.7; Figure 1C). A significant increase in 
glutamine: glutamate ratio was also apparent (baseline 0.35 ± .07, IFN 0.43 ± .08, 
p<0.01; Figure 1A). Concentrations estimates for both metabolites were obtained with 
low estimated errors (CRLB glutamate 4.8% ± .7, glutamine 11.3% ± 3.0). The 
majority (eight) of these participants were taking no concomitant medication, the 
others were taking vitamin supplements, erythromycin, oral contraceptive and an 
antihistamine, respectively. 
Figure 1 near here 
 
No significant effect of IFN was observed on other MRS measures relative to creatine 
(choline, NAA, inositol; p>0.2 all cases). No significant correlation was observed 
between change in viral load and any MRS measure. A secondary analysis of 
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concentrations relative to tissue water showed the same pattern of effect, with a 
significant effect of IFN on glutamine (p=0.03) but not on other measures (p>0.3 in 
all cases). 
Figure 2 near here 
 
The observed change in cortical glutamine concentration correlated with symptom 
ratings at the time of the second scan (Figure 2) for depression (QIDS: r .68, p=0.02), 
and anxiety (STAI: r .69, p=0.02), but not fatigue (FSS: p>0.8). Anxiety scores also 
correlated with change in glutamine:glutamate ratio (r .68, p=0.02). 
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Discussion 
Our findings suggest that treatment with IFN-α over four to six weeks leads to an 
increase in glutamine levels in anterior cingulate cortex. However, levels of glutamate 
were unchanged. Interestingly, this increase in glutamine showed some correlation 
with measures of depression and anxiety. This effect on cortical glutamine has not to 
our knowledge previously been described. 
 
The cycling of glutamine and glutamate is a key process in the control of glutamate 
neurotransmission. Glutamate released from synaptic terminals is taken up into 
astrocytes where it is converted to glutamine by the enzyme, glutamine synthetase. 
Glutamine is subsequently released by astrocytes and accumulates in glutamatergic 
neurones where it is converted back to glutamate by glutaminase. Our data suggest 
that IFN-α treatment is associated with an increase in glutamine relative to glutamate. 
This might be consistent with increased turnover of glutamate, because with elevated 
glutamate levels one would expect more glutamate to be made available for astrocytes 
for conversion to glutamine (Yüksel et al. 2010). Because glutamate itself can be 
neurotoxic there are several mechanisms which prevent glutamate levels becoming 
excessive, particularly uptake into astrocytes (Danbolt 2001). Functional 
interpretation of changes in spectroscopic measures is not always straightforward, 
however there is growing evidence that increased glutamine relative to glutamate is 
consistent with glutamatergic overactivity (Ongur et al, 2008) and thus altered resting 
state activity (Alcaro et al, 2009). Given the well established role of medial prefrontal 
cortex including anterior cingulate in emotional processing and mood disorders 
(Strakowski et al, 2012; Kupfer et al, 2012) such changes are well placed to influence 
risk of developing depression. 
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As noted above, accurately differentiating glutamine from glutamate with MRS is 
often challenging. Methods such as those used here with very short echo times assist 
in precise glutamate quantitation (Wijtenburg and Knight-Scott 2011). In this study, 
as in previous reports with this particular technique (Mekle et al. 2009), both 
glutamine and glutamate were measured with low errors, lending confidence to the 
finding that glutamine increases relative to glutamate during IFN-α treatment. 
 
There are a number of processes by which IFN-α might increase glutamate release. 
IFN-α has been shown to elevate CSF levels of quinolinic acid which can increase 
glutamate release from synaptosomes (Raison et al. 2010). Inflammatory mediators 
can also lead to decreased uptake of glutamate into astrocytes which could result in 
increased synaptic glutamate levels (McNally et al. 2008). However, diminished 
glutamate uptake into astrocytes would not be expected to be lead to increased 
glutamine as observed here, because of reduced access of glutamate to the astrocytic 
enzyme, glutamine synthetase. 
 
It is possible to elevate central glutamine concentrations in people with hepatic 
cirrhosis by inducing hyperammonaemia (Mardini et al. 2011). This effect is 
associated with compensatory reductions in myo-inositol concentrations (Mardini et 
al. 2011). A similar pattern can be observed when cirrhosis is accompanied by hepatic 
encephalopathy (Haussinger et al. 1994, Weissenborn et al. 2007). In this study we 
excluded patients with evidence of cirrhosis a priori to avoid this potential confound. 
The absence of any decrease in myo-inositol levels makes it less likely that the effect 
on glutamine seen here can be explained by alterations in circulating ammonia but it 
could be of interest in future studies to measure this directly. While participants in this 
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study were recruited from a general clinic population, replication in other samples 
would increase confidence further that the effect seen is generalisable. 
 
In a previous IFN study, increased CSF levels of quinolinic acid were  reported to 
correlate with scores on the Montgomery-Åsberg Depression Rating Scale during 
IFN-α treatment (Raison et al. 2010). We also saw a correlation between increases in 
cortical glutamine and the depression and anxiety ratings. It clearly would be of 
interest to measure both glutamine and quinolinic acid in patients receiving IFN-α to 
see whether the concentrations of these two neurochemicals correlate with each other 
and with depression scores. 
 
It is known that chronic hepatitis C viral infection can affect mental state in the 
absence of IFN-α treatment, and indeed that it can be associated with MRS 
abnormalities such as elevated levels of choline (Forton et al. 2001). A recent study 
found that elevated basal ganglia choline and inositol reduced in people with 
sustained response to antiviral treatment (Byrnes et al. 2012). This study lacks the 
statistical power to investigate such subgroup effects robustly. Previous studies have 
not used MRS techniques optimised to specifically identify alterations in glutamine 
levels such as those described here. The pre-treatment glutamine:glutamate ratios 
found here are similar to those in healthy volunteers at our centre with this 
combination of MRS acquisition and analysis (Figure 1A) suggesting that IFN-α 
treatment is causing a change rather than normalising a baseline abnormality, but 
clearly further investigation of baseline effects of viral infection on such measures 
would be of interest. Potential participants with current axis I disorders were excluded 
from taking part in this study. If participants with existing depression at baseline had 
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been included, this might have affected the magnitude of neurochemical effects seen 
and could be investigated in future studies. 
 
There have been several studies using MRS to examine cortical glutamate levels in 
patients experiencing major depressive episodes. Generally in patients with current 
unipolar depression, MRS levels of total glutamate and glutamine are reported to be 
lower than controls while elevated levels are associated with bipolar depression 
(Yüksel and Öngür 2010). It also appears that unipolar depression tends to be 
associated with a reduction of the ratio of glutamine relative to glutamate (Yüksel and 
Öngür 2010). If this is the case, the neurochemical changes produced by IFN-α as 
measured by MRS appear distinct from those seen in unipolar depression. This raises 
the possibility that depression associated with inflammation may have a profile of 
glutamatergic changes more similar to that seen in bipolar depression. 
 
A similarity in emergent neurochemical profile in this model and that seen in bipolar 
depression  may be of particular interest given recent reports of emergent manic or 
mixed affective episodes during IFN treatment (Constant et al. 2005) and association 
of the presence of trait markers of vulnerability to bipolar disorder with higher rates of 
psychiatric complications of IFN treatment (Lim et al. 2010). The changes seen in 
glutamate activity in major depression and bipolar disorder seem relatively 
independent of concomitant psychotropic medication. In the present study the effect 
observed cannot be secondary to psychotropic medication, which would have the 
greatest potential to influence MRS results, however some participants were taking 
medication for physical reasons. We tried to deal with this as far as we could by only 
recruiting patients whose drug treatment was stable. We suspect that it might be 
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impracticable to recruit a group of hepatitis C patients receiving IFN who are 
otherwise medication-free.      
  
Here we have observed that treatment with IFN-α over four to six weeks leads to an 
increase in glutamine levels in anterior cingulate cortex. This effect correlates with 
depressive symptoms but the neurochemical effect seen differs from that observed in 
unipolar depression. This may have implications for the management and prevention 
of IFN-induced depression. Our study requires replication in a larger group of IFN-
treated participants where it would also be desirable to have a direct comparison 
group of patients with major depression. 
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Participant characteristics. n=12 except where indicated. Means with standard 
deviations. *: p<.05 difference between baseline and treatment 
 
Figure 1. 
A: Glutamine:glutamate ratio at baseline and during treatment with interferon-a 
(IFN). Bar: reference values (mean and standard deviation) for healthy controls with 
this method. 
B: Sample SPECIAL spectrum and voxel position in anterior cingulate cortex. 
C: MRS measures at baseline (white) and during interferon treatment (grey). NAA:N-
acetyl-aspartate. *: p<.05. 
 
Figure 2. 
Change in glutamine against mental state during treatment. QIDS: Quick Inventory of 
Depressive Symptomatology, STAI: Spielberger state anxiety, FSS: Fatigue Severity 
Scale. Significant correlations with QIDS (r .68, p=.02) and STAI (r .69, p=.02). 
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Table 1. 
 Baseline (n=12) During interferon 
treatment (n=12) 
Age (yr) 38.5 ± 10.5 - 
Gender 8 male, 4 female - 
QIDS-SR16 3.67 ± 3.53 7.67 ± 4.66 * 
State anxiety 32.2 ± 7.42 35.2 ± 9.48 
Fatigue Severity Scale 2.69 ± 1.23 (n=9) 3.86 ± 1.33 (n=10) 
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